Effectiveness and safety of Hongjin Xiaojie Capsule versus waiting list for breast pain
| ISRCTN | ISRCTN44184398 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN44184398 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsor | Yunnan Yousheng Pharmaceutical Co., Ltd |
| Funder | Yunnan Yousheng Pharmaceutical Co., Ltd |
- Submission date
- 13/08/2019
- Registration date
- 18/08/2019
- Last edited
- 06/09/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Plain English summary of protocol
Background and study aims
Breast pain, with different degrees of pain in the breast, belongs to the category of "lump in breast" in traditional Chinese medicine. It mainly includes two types: periodic breast pain and non-periodic breast pain. Cyclical pain is the most common type to date, and the incidence can account for 70% of breast pain. The clinical manifestations are diffused pain or tenderness in one or both breasts, and breast swelling may increase or decrease with the menstrual cycle. It seriously affects the quality of life of women. Hormone therapy is usually used in clinical practice, but the side effects are usually significant, and long-term use may interfere with endocrine regulation. The Chinese herbal medicine Hongjin Xiaojie capsule belongs to Chinese patent medicine. It is known as the "female holy medicine" and has the effect of detumescence and pain, soft firmness and loose knot, promoting blood circulation and removing blood stasis, soothing liver and regulating qi. Hongjin Xiaojie capsule is originated from the century-old minority Yi folk medicine classics, and is widely used in Yi nationality areas, especially in Yunnan province. It was approved as a herbal drug by the China Food and Drug Administration in 1999, and it was included in the Guidelines for Clinical Application of Chinese Medicines in 2017. It is listed as an optional Chinese patent medicine for breast pain. The aim of this study is to evaluate the clinical effectiveness and safety of Chinese patent medicine Hongjin Xiaojie capsule in the treatment of breast pain.
Who can participate?
Premenopausal or perimenopausal women with breast pain aged 18 to 55 years old
What does the study involve?
Participants are randomly allocated into two groups. One group receives Hongjin Xiaojie capsule for three months (not taking the medicine during menstruation). The other group receives no treatment during the first three months. After three months, the participants in the waiting list group can volunteer to take the test medicine for three months.
What are the possible benefits and risks of participating?
If successful, the medicine has the potential to preserve and enhance the benefits of rehabilitation for women with breast pain. This may reduce hospital admissions and improve their quality of life. There may be some minor adverse effect associated with this medicine in a few patients.
Where is the study run from?
1. The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China
2. Beijing Fang Shan District Hospital of Chinese Medicine, Beijing, China
3. Sichuan Second Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China
4. Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine, Shanghai, China
When is the study starting and how long is it expected to run for?
August 2019 to December 2021 (updated 08/01/2021, previously: December 2020)
Who is funding the study?
Yunnan Yousheng Pharmaceutical Co., Ltd. (China)
Who is the main contact?
1. Jian-ping Liu (Scientific)
Liujp@bucm.edu.cn
2. Xiao-hua Pei (Public)
pxh_127@163.com
Contact information
Scientific
11 Bei San Huan Dong Lu
Chaoyang District
Beijing
100029
China
 ORCID ID |
0000-0002-0320-061X |
|---|---|
| Phone | +86 (0)10 64286760 |
| Liujp@bucm.edu.cn |
Public
No. 51, Xiao Guan Jie
An Ding Men Wai
Chaoyang District
Beijing
100029
China
| Phone | +86 (0)13911683278 |
|---|---|
| pxh_127@163.com |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicentre randomized clinical trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Effectiveness and safety of Hongjin Xiaojie Capsule versus waiting list for breast pain: a multi-center, randomized controlled trial |
| Study objectives | Compared with no treatment, Chinese herbal medicine Hongjin Xiaojie capsule may be effective and safe for relieving breast pain in women. |
| Ethics approval(s) | Approved 31/07/2019; IRB of The Third Affiliated Hospital, Beijing University of Chinese Medicine (No. 51 Xiao Guan Jie, An Ding Men Wai, Chaoyang District, Beijing; Tel: +86 (0)10-52075242; Email: zydsyky@126.com); Approval number: BZYSY-2019KYKTPJ-05 |
| Health condition(s) or problem(s) studied | Breast pain |
| Intervention | Participants will be randomly allocated into two groups. The method of randomisation: central randomisation run by the leading clinical site (3rd Affiliated Hospital of Beijing University of Chinese Medicine), and the generation of allocation sequence was developed by random number tables. The treatment group will receive Hongjin Xiaojie capsules for three months (stop taking this medicine during menstruation), 3 times/day The control (waiting list) group will receive no treatment during the first three months. After three months, the participants can volunteer to take the tested medicine for three months The dosage given: 4 capsules/time, three times per day Co-intervention (analgesic drug) will be allowed if patients feel pain not well controlled The total duration of follow-up: 24 weeks ± 3 days |
| Intervention type | Drug |
| Phase | Phase IV |
| Drug / device / biological / vaccine name(s) | Hongjin Xiaojie capsule |
| Primary outcome measure(s) |
1. The degree of breast pain measured using short-form of McGill questionnaire (SF-MPQ) at baseline, 4 weeks ± 3 days (duration of treatment), 8 weeks ± 3 days (duration of treatment), 12 weeks ± 3 days (end of treatment), 24 weeks ± 3 days (end of follow-up) |
| Key secondary outcome measure(s) |
1. Breast nodule size: the size of the nodule is determined by both palpation and B-ultrasound at baseline, 12 weeks ± 3 days (end of treatment) |
| Completion date | 31/12/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 55 Years |
| Sex | Female |
| Target sample size at registration | 294 |
| Total final enrolment | 298 |
| Key inclusion criteria | 1. 18 - 55 years old, female, pre- or peri-menopause 2. Meeting the diagnostic criteria of breast pain; including women with breast nodules, the longest diameter of B-ultrasonic solid nodules ≤2cm or the longest diameter of B-ultrasonic cystic nodules ≤2 cm 3. The number of days of breast pain for each menstrual cycle is equal or longer than 3 days and visual analog scale (VAS) ≥ 4 points; if treated before, the pain symptom could not relieve for three consecutive menstrual cycles or more 4. Women diagnosed as hysteromyoma according to the diagnostic criteria of hysteromyoma will be included 5. The menstrual cycle and the menstrual period are basically regular, and the menstrual cycle is about 28 ± 7 days |
| Key exclusion criteria | 1. Women who are preparing for pregnancy or who are pregnant or lactating 2. Patients with allergic constitution, or allergic to the test drug or its components 3. Breast image report and data system (BI-RADS) classification > level 3 4. Patients with breast malignant tumors, inflammatory diseases and other endocrine diseases (such as pituitary tumors) 5. Taking contraceptives during the trial and using hormonal drugs within the first three months of screening 6. Those who have taken Chinese or Western medicines to treat this disease within 1 month before screening or those who participated in other clinical drug trials 7. Patients with severe primary diseases including cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, or patients with mental illness |
| Date of first enrolment | 01/10/2019 |
| Date of final enrolment | 31/10/2021 |
Locations
Countries of recruitment
- China
Study participating centres
Beijing
100029
China
Beijing
100029
China
Chengdu
610000
China
Shanghai
200000
China
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The data sharing plans for the current study are limited upon the contract with the company and might be made available upon agreement from the company. Data requests will be directed to Prof Jian-ping Liu at the Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China; Tel: +86 (0)10 64286760; Email: Liujp@bucm.edu.cn. Since this trial was sponsored by the pharmaceutical company (Yunnan Yousheng) and there is a contract between the company and the trial institutions, any request of data will need approval through the negotiation of the PI and the company and in accordance with the regulation of ethical and personal privacy policy in China. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 20/08/2024 | 06/09/2024 | Yes | No | |
| Other unpublished results | 07/03/2024 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Additional files
- ISRCTN44184398 Summary of research results.pdf
- Other unpublished results
Editorial Notes
06/09/2024: Publication reference added.
07/03/2024: A file of unpublished results was added.
05/01/2022: The following changes have been made:
1. The participant information sheet field has been added.
2. The total final enrolment number has been added.
08/01/2021: The following changes were made to the trial record:
1. The overall end date was changed from 31/12/2020 to 31/12/2021.
2. The recruitment end date was changed from 30/06/2020 to 31/10/2021.
3. The plain English summary was updated to reflect these changes.
4. The intention to publish date was changed from 31/12/2020 to 31/12/2021.
16/08/2019: Trial's existence confirmed by ethics committee.
